Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc (ELDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,115
  • Shares Outstanding, K 24,813
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,330 K
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59
Trade ELDN with:

Options Overview Details

View History
  • Implied Volatility 143.74% ( +0.99%)
  • Historical Volatility 109.78%
  • IV Percentile 23%
  • IV Rank 10.32%
  • IV High 807.51% on 03/27/24
  • IV Low 67.38% on 11/16/23
  • Put/Call Vol Ratio 0.26
  • Today's Volume 103
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 610
  • Open Int (30-Day) 615

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.37
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +50.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +55.92%
on 04/15/24
2.43 -2.47%
on 04/29/24
+0.31 (+15.05%)
since 03/28/24
3-Month
1.52 +55.93%
on 03/15/24
2.43 -2.47%
on 04/29/24
+0.51 (+27.42%)
since 01/29/24
52-Week
1.07 +121.50%
on 11/09/23
2.95 -19.66%
on 05/10/23
+0.27 (+12.86%)
since 04/28/23

Most Recent Stories

More News
2 Penny Stocks That Wall Street Predicts Will Soar Over 300%

While these two penny stocks have the potential for exceptional returns, they also carry greater risk and volatility.

ELDN : 2.37 (+15.05%)
ABOS : 3.18 (+0.32%)
MRNA : 111.62 (+3.38%)
$SPX : 5,116.17 (+0.32%)
Lexaria Bioscience (NASDAQ: LEXX) Tracking Path to Drug Delivery Innovation, Commercialization

Lexaria Bioscience’s (NASDAQ: LEXX) path to becoming a global leader and innovator in drug delivery traces its origins to 2014, when CEO Chris Bunka redirected the company to its current business, focusing...

ELDN : 2.37 (+15.05%)
LEXX : 2.46 (+4.68%)
Lexaria Bioscience (NASDAQ: LEXX) Appoints New Board Member

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD,...

AGN.AX : 0.575 (+6.48%)
LEXX : 2.46 (+4.68%)
ELDN : 2.37 (+15.05%)
ABBV : 161.52 (+1.19%)
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”)...

ELDN : 2.37 (+15.05%)
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage...

ELDN : 2.37 (+15.05%)
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage...

ELDN : 2.37 (+15.05%)
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated...

ELDN : 2.37 (+15.05%)
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial...

ELDN : 2.37 (+15.05%)
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Management to host conference call and webcast at 4:30 p.m. ET...

ELDN : 2.37 (+15.05%)
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage...

ELDN : 2.37 (+15.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 2.90
2nd Resistance Point 2.66
1st Resistance Point 2.52
Last Price 2.37
1st Support Level 2.14
2nd Support Level 1.90
3rd Support Level 1.76

See More

52-Week High 2.95
Last Price 2.37
Fibonacci 61.8% 2.23
Fibonacci 50% 2.01
Fibonacci 38.2% 1.79
52-Week Low 1.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar